Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday. The firm presently has a $0.75 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 1.35% from the company’s current price.

According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “

Several other research analysts have also recently issued reports on the stock. B. Riley set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, December 27th. Maxim Group set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, December 27th. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Finally, Roth Capital restated a “buy” rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Five investment analysts have rated the stock with a buy rating, Actinium Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $3.75.

Shares of Actinium Pharmaceuticals (ATNM) traded up $0.01 during trading on Tuesday, hitting $0.74. 504,400 shares of the stock traded hands, compared to its average volume of 569,044. Actinium Pharmaceuticals has a fifty-two week low of $0.54 and a fifty-two week high of $1.72. The firm has a market cap of $59.22, a PE ratio of -1.57 and a beta of 41.30.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/16/actinium-pharmaceuticals-atnm-rating-increased-to-buy-at-zacks-investment-research-2.html.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.